38527-50-3

Basic information

• Product Name: 4H-3,1-Benzoxazin-4-one, 6-Methoxy-2-Methyl-
• Synonyms: 4H-3,1-Benzoxazin-4-one, 6-Methoxy-2-Methyl-;6-methoxy-2-methyl-4H-benzo[d][1,3]oxazin-4-one
• CAS NO: 38527-50-3
• Molecular Formula: C₁₀H₉NO₃
• Molecular Weight: 191.18336
• Mol File: 38527-50-3.mol

Chemical Properties

• Boiling Point: 341.9±44.0 °C(Predicted)
• Appearance: /
• Density: 1.27±0.1 g/cm3(Predicted)
• PKA: 2.41±0.20(Predicted)
• CAS DataBase Reference: 4H-3,1-Benzoxazin-4-one, 6-Methoxy-2-Methyl-(CAS DataBase Reference)
• NIST Chemistry Reference: 4H-3,1-Benzoxazin-4-one, 6-Methoxy-2-Methyl-(38527-50-3)
• EPA Substance Registry System: 4H-3,1-Benzoxazin-4-one, 6-Methoxy-2-Methyl-(38527-50-3)

Safety Data

• Hazardous Substances Data: 38527-50-3(Hazardous Substances Data)

Upstream product

• 108-24-7 acetic anhydride 
• 6705-03-9 2-Amino-5-methoxybenzoic acid 
• 42454-06-8 2-nitro-5-hydroxybenzaldehyde 
• 20357-24-8 5-methoxy-2-nitro-benzaldehyde 
• 100-83-4 meta-hydroxybenzaldehyde 
• 201230-82-2 carbon monoxide 
• 191348-14-8 2-iodo-4-methoxylaniline 
• 1882-69-5 5-methoxy-2-nitro-benzoic acid 

Downstream Products

• 101877-86-5 acetic acid-(4-methoxy-2-o-toluoyl-anilide) 
• 38985-80-7 2-(acetylamino)-5-methoxybenzoic acid 
• 62175-51-3 5-(2-acetylamino-5-methoxy-phenyl)-oxazole-4-carboxylic acid methyl ester 
• 108716-13-8 2-amino-5-methoxy-2'-methyl-benzophenone 
• 166973-19-9 1-[2-amino-5-(methyloxy)phenyl]-2-methyl-1-propanone 
• 880875-40-1 N-[2-(1,3-benzodioxol-5-ylcarbonyl)-4-(methyloxy)phenyl]acetamide 
• 1237744-90-9 4-(6-methoxy-2-methyl-4-oxoquinazolin-3(4H)-yl)benzamide 
• 1237744-94-3 3-(6-methoxy-2-methyl-4-oxoquinazolin-3(4H)-yl)benzoic acid 
• 1237744-75-0 4-(6-methoxy-2-methyl-4-oxoquinazolin-3(4H)-yl)benzoic acid 
• 1237744-89-6 4-(6-methoxy-2-methyl-4-oxoquinazolin-3(4H)-yl)benzonitrile 
• 1237744-91-0 methyl 4-(6-methoxy-2-methyl-4-oxoquinazolin-3(4H)-yl)benzoate 
• 91713-54-1 [2-amino-5-(methyloxy)phenyl](4-chlorophenyl)methanone 
• 1300090-44-1 phenylmethyl (1-(1H-1,2,3-benzotriazol-1-yl)-2-{[2-[(4-chlorophenyl)carbonyl]-4-(methyloxy)phenyl]amino}-2-oxoethyl)carbamate 
• 1300019-48-0 methyl N¹-[2-[(4-chlorophenyl)carbonyl]-4-(methyloxy)phenyl]-N²-{[(9H-fluoren-9-ylmethyl)oxy]carbonyl}-L-α-asparaginate 

Relevant articles and documents

THERAPEUTIC COMPOSITION OF CURE-PRO COMPOUNDS FOR TARGETED DEGRADATION OF BET DOMAIN PROTEINS, AND METHODS OF MAKING AND USAGE

The present application is directed to a therapeutic composition, comprising two precursor compounds (monomers) that are suitable for assembly via two or more reversible covalent bonds. The monomers are polyfunctionalized molecules comprising a bioorthogo

THERAPEUTIC CURE-PRO COMPOUNDS FOR TARGETED DEGRADATION OF BET DOMAIN PROTEINS, AND METHODS OF MAKING AND USING THEM

The present application is directed to a therapeutically useful compound, comprised of two monomers that are linked to each other through two or more reversible covalent bonds. Each monomer is a polyfunctionalized molecule comprising a bioorthogonal linker element and ligand or pharmacophore, wherein the linker and ligand/pharmacophore are covalently coupled to each other either directly or through an optional connector moiety.

PROTEIN TAG TO INDUCE LIGAND DEPENDENT DEGRADATION OF PROTEIN/PROTEIN-FUSIONS

Disclosed is a dTAG system comprising small molecule degraders of mutant BET family protein-tagged proteins via recruitment of an E3 ubiquitin ligase and uses thereof.

METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE

The present disclosure relates to compounds and methods for modulating the expression of dmpk, and treating diseases and conditions in which dmpk plays an active role. The compound can be a transcription modulator molecule having a first terminus, a second terminus, and oligomeric backbone, wherein: a) the first terminus comprises a DNA-binding moiety capable of noncovalently binding to a nucleotide repeat sequence CAG or CTG; b) the second terminus comprises a protein-binding moiety binding to a regulatory molecule that modulates an expression of a gene comprising the nucleotide repeat sequence CAG or CTG; and c) the oligomeric backbone comprising a linker between the first terminus and the second terminus.

Recyclable palladium-catalyzed carbonylative annulation of 2-iodoanilines with acid anhydrides: A practical synthesis of 2-alkylbenzoxazinones

A highly efficient heterogeneous palladium-catalyzed carbonylative annulation of 2-iodoanilines and acid anhydrides has been developed. The reaction proceeds effectively in toluene using N,N-diisopropylethylamine (DiPEA) as the base at 100 °C under 2 bar of CO and provides a novel, general, and practical method for the assembly of a wide variety of 2-alkylbenzoxazinones with high functional group tolerance and good to excellent yields. This supported palladium complex can be readily separated from the product and recovered by a simple filtration of the reaction solution and reused up to seven times with almost consistent catalytic efficiency.

BENZIMIDAZOLES DERIVATIVES AS ANTI-TUBERCULOSIS AGENTS

The present invention provides novel compounds of benzimidazole derivatives as anti-tubercular agents and their pharmaceutically acceptable salts for use as bactericidal therapeutics. The invention also provides a pharmaceutical composition comprising a c

Evaluation of linker length effects on a BET bromodomain probe

Fueled by the therapeutic potential of the epigenetic machinery, BET bromodomains have seen high interest as drug targets. Herein, we introduce different linkers to a BET bromodomain benzodiazepine ligand (I-BET762) to gauge its implications in the develo

Scaffold Morphing To Identify Novel DprE1 Inhibitors with Antimycobacterial Activity

We report a novel benzimidazole (BI) based DprE1 inhibitor that resulted from scaffold morphing of a 1,4-azaindole series. The clinical progression of the 1,4-azaindole series from our previous work validates the potential of exploring newer chemical enti

Preparation method of antiviral drug intermediate benzodiazepinone derivative

The invention relates to a preparation method of an antiviral drug intermediate and in particular to a preparation method of 7-hydroxyl-5-(1H-pyrrole-2-yl)-1H-benzo[e][1,4]-diaza-2(3H)-one. The preparation method comprises the following steps: by taking 2-amino-5-methoxyl benzoic acid as a raw material, opening a pyrrole ring by applying a Grignard reagent after acetic acid cyclization; removing acetate under the action of sodium hydroxide to obtain an amino functional group compound (II); combining the compound (II) with chloroacetyl chloride; performing a substitution reaction under the action of ammonia water to convert chlorine into an amine compound (V); and closing the ring of the compound (V) through trimethylacetic acid and forming 7-hydroxyl-5-(1H-pyrrole-2-yl)-1H-benzo[e][1,4]-diaza-2(3H)-one (VII) under the action of boron tribromide. The invention provides a brand new compound and a synthetic route for the antiviral drug activity intermediate; the reaction steps are easily controlled, and stable industrial production and preparation can be realized.

Enantioselective Synthesis of 3-Arylquinazolin-4(3H)-ones via Peptide-Catalyzed Atroposelective Bromination

We report the development of a tertiary amine-containing β-turn peptide that catalyzes the atroposelective bromination of pharmaceutically relevant 3-arylquinazolin-4(3H)-ones (quinazolinones) with high levels of enantioinduction over a broad substrate scope. The structure of the free catalyst and the peptide-substrate complex were explored using X-ray crystallography and 2D-NOESY experiments. Quinazolinone rotational barriers about the chiral anilide axis were also studied using density functional theory calculations and are discussed in light of the high enantioselectivities observed. Mechanistic studies also suggest that the initial bromination event is stereodetermining, and the major monobromide intermediate is an atropisomerically stable, mono-ortho-substituted isomer. The observation of stereoisomerically stable monobromides stimulated the conversion of the tribromide products to other atropisomerically defined products of interest. For example, (1) a dehalogenation Suzuki-Miyaura cross-coupling sequence delivers ortho-arylated derivatives, and (2) a regioselective Buchwald-Hartwig amination procedure installs para-amine functionality. Stereochemical information was retained during these subsequent transformations.